a public good project by the
Synthesis
Company
of California

© 2026

Sebastian Schellong | doi.page

0 works0 citations0 h-index

Sebastian Schellong

Städtisches Klinikum Dresden(DE)Krankenhaus Dresden-Friedrichstadt(DE)Imam Reza Hospital(IR)

Publications by Year

Research Areas

Venous Thromboembolism Diagnosis and Management, Atrial Fibrillation Management and Outcomes, Diagnosis and Treatment of Venous Diseases, Blood Coagulation and Thrombosis Mechanisms, Central Venous Catheters and Hemodialysis

Most-Cited Works

→ Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism(2009)2,554 cited
→ Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism(2014)1,599 cited
→ Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism(2013)979 cited
→ Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis(2013)925 cited
→ Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial(2018)700 cited
→ Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients(2013)598 cited

→ A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study(2008)

345 cited

→ Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)(2007)340 cited

→ Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism(2017)336 cited

→ Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study(1998)260 cited